IMM5605-12C10

IMM5605-12C10 is a bispecific antibody-trap developed by ImmuneOnco Biopharmaceuticals, designed to target both CD38 and CD47 for the treatment of hematologic malignancies. It consists of a CD38-targeting antibody fused to a CD47 ligand trap in an ADCC-enhanced IgG1 format. The molecule is engineered to have high affinity for CD38 and low affinity for CD47, which minimizes binding to red blood cells (RBCs) and reduces off-tumor toxicity. Its mechanism of action involves the simultaneous engagement of CD38 and CD47 on tumor cells, leading to the blockade of the CD47/SIRPα "don't eat me" signal, inhibition of CD38 enzymatic activity (reducing adenosine production), and induction of potent antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). In preclinical models, IMM5605-12C10 has demonstrated superior efficacy compared to monospecific anti-CD47 or anti-CD38 therapies, including complete tumor eradication in multiple myeloma xenografts.